Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY JN.1? COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19 ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...